Medimix Hematology
  • Home
  • Live from the congress
    • 2025
      • EHA 2025
      • ICML 2025
      • EBMT 2025
    • 2024
      • ASH 2024 (San Diego)
      • EHA 2024 (Madrid)
      • ASCO 2024 (Chicago)
  • Contact
  • Other specialties
    • Dermatology
    • Oncology
  • SIGN UP
  • SIGN IN
    • Login
ASH 2023

A 46 long non-coding RNAs expression signature as independent prognostic factor in pediatric AML

December 10, 2023

Approximately 30% of pediatric AML patients encounter relapse, emphasizing the imperative need for refining risk stratification in this cohort. Consequently, Zhiyao Ren, PhD student at University Hospital Ghent, constructed a signature comprising 46 lncRNAs associated with relapse and assessed its prognostic efficacy for RFS in pediatric AML.

Internal validation substantiated the robust performance of the signature in predicting 1, 2, and 3-year RFS. Moreover, external validation across independent cohorts corroborated its prognostic utility, establishing the signature as an independent prognostic determinant. Intriguingly, our signature not only served as an independent predictor of RFS but also stratified patients into distinct risk groups, thereby diverging from conventional risk classification factors.

Reference:

Ren Z, ASH 2023. #1569

With the educational support of:

Tags:

poster

Share Article

Medimix Hematology

Website created by MediMix © 2025 - Privacy Policy

  • Home
  • Live from the congress
    • 2025
      • EHA 2025
      • ICML 2025
      • EBMT 2025
    • 2024
      • ASH 2024 (San Diego)
      • EHA 2024 (Madrid)
      • ASCO 2024 (Chicago)
  • Contact
  • Other specialties
    • Dermatology
    • Oncology
  • SIGN UP
  • SIGN IN
    • Login
    • Logout
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok